Financial Performance - The group's unaudited revenue for the nine months ended September 30, 2021, was approximately SGD 7,491,000, an increase of about SGD 2,665,000 or 55.2% compared to SGD 4,826,000 for the same period in 2020[4]. - The group's unaudited loss for the nine months ended September 30, 2021, was approximately SGD 4,171,000, an increase of about SGD 3,216,000 or 336.8% compared to a loss of SGD 955,000 for the same period in 2020[4]. - The loss per share for the nine months ended September 30, 2021, was approximately 0.58 Singapore cents, compared to a loss per share of 0.16 Singapore cents for the same period in 2020[4]. - Total comprehensive loss for the nine months ended September 30, 2021, was SGD 4,268,000, compared to a total comprehensive loss of SGD 980,000 for the same period in 2020[7]. - The total loss before tax for the nine months ended September 30, 2021, was SGD 4,031,000, compared to a loss of SGD 1,067,000 for the same period in 2020[43]. - The company reported a loss attributable to owners of SGD 4,171,000 for the nine months ended September 30, 2021, compared to a loss of SGD 955,000 for the same period in 2020[52]. Revenue Breakdown - Total revenue for medical services reached SGD 7,393,000 for the nine months ended September 30, 2021, compared to SGD 5,024,000 for the same period in 2020, representing a year-over-year increase of approximately 47.2%[41]. - Revenue from beauty services was SGD 399,000, while consultation services generated SGD 1,470,000, and prescription and dispensing services contributed SGD 2,181,000 for the nine months ended September 30, 2021[41]. - Other service revenue increased from approximately SGD 503,000 for the nine months ended September 30, 2020, to approximately SGD 1,116,000 for the nine months ended September 30, 2021, representing a growth of about 121%[63]. - Revenue from consultation services increased from approximately SGD 980,000 to SGD 1,470,000, with patient visits rising by about 41.2% from 12,537 to 17,708[62]. Expenses and Costs - Employee benefit expenses amounted to approximately SGD 4,196,000, an increase of about SGD 2,448,000 or 140% compared to SGD 1,748,000 for the same period in 2020[4]. - The company’s interest expenses for borrowings increased to SGD 143,000 from SGD 31,000 in the previous year[7]. - The cost of consumables and medical supplies rose from approximately SGD 759,000 for the nine months ended September 30, 2020, to approximately SGD 1,342,000 for the nine months ended September 30, 2021, an increase of about 77%[64]. - Other operating expenses increased by approximately SGD 536,000 or 15.5%, from about SGD 3,450,000 for the nine months ended September 30, 2020, to approximately SGD 3,986,000 for the nine months ended September 30, 2021[74]. Corporate Governance and Compliance - The company has complied with all applicable corporate governance code provisions for the nine months ending September 30, 2021[99]. - The board of directors consists of five members, including three executive directors and two independent non-executive directors, following recent changes in board composition[98]. - The company is committed to maintaining high standards of corporate governance to manage business risks and enhance transparency[95]. - The audit committee has reviewed the unaudited condensed consolidated financial statements for the nine months ending September 30, 2021, and provided opinions and recommendations[110]. Dividends and Share Placement - The board does not recommend the payment of any dividend for the nine months ended September 30, 2021[4]. - The company plans to issue up to 144,000,000 placement shares at a price of HKD 0.135 per share as part of a placement agreement signed on September 27, 2021[82]. - The company successfully placed 144,000,000 new shares at a price of HKD 0.135 per share, increasing total shares from 720,000,000 to 864,000,000[84]. - The net proceeds from the placement amounted to approximately HKD 19,148,000, with 40% allocated for purchasing medical imaging equipment, 30% for general working capital, and 30% for potential investments[84]. Financial Reporting and Standards - The unaudited consolidated financial statements for the nine months ended September 30, 2021, were prepared in accordance with International Financial Reporting Standards and presented in Singapore dollars[14]. - The group adopted all new and revised International Financial Reporting Standards effective for annual periods beginning on or after January 1, 2021, with no significant impact on accounting policies or reported amounts[17]. - The financial statements were prepared based on historical cost, with fair value measurements considered for assets and liabilities[18]. - The group recognized expected credit losses for debt instruments measured at amortized cost or fair value through other comprehensive income, updating the expected credit loss amounts at each reporting date[22]. Operational Developments - The company established a Mohs micrographic surgery center and a Mole Mapping center, enhancing its service offerings with three Mohs dermatologists[56]. - The company acquired a Siemens Healthineers MAGNETOM Lumina and a Revolution CT, aiming to expand its medical imaging services[57]. - The company plans to enhance its service offerings through the acquisition of new medical equipment focused on preventive and proactive care[86]. - The company has not reported any significant events affecting its operations since September 30, 2021[87].
德斯控股(08437) - 2021 Q3 - 季度财报